OSR Health (OSRHW) Cash from Restructuring (2025)

OSR Health (OSRHW) posted Cash from Restructuring of -$57708.0 for Q4 2025, down 162.49% sequentially from $92341.0 in Q3 2025.

OSR Health (OSRHW) Cash from Restructuring (2025) Analysis & Trends

OSR Health has reported Cash from Restructuring for 1 years, with the latest figure at -$57708.0 in Q4 2025.

Quarterly Cash from Restructuring changed N/A year-over-year to -$57708.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.6 million (changed N/A YoY) and the FY2025 annual result came in at $8.6 million, changed N/A from the prior year.
Cash from Restructuring retreated to -$57708.0 in Q4 2025 per OSRHW's latest filing, from $92341.0 in the prior quarter.
Over five years, Cash from Restructuring peaked at $8.5 million in Q1 2025 and troughed at -$57708.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.97 Bn	131.12 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.15 Bn	77.15 Bn	3.93 Bn
3	Argenx Se	62.84 Bn	57.65 Bn	1.37 Bn
4	Moderna	55.74 Bn	50.60 Bn	52.00 Mn
5	BeOne Medicines	41.53 Bn	36.43 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.60 Bn	28.29 Bn	992.69 Mn
7	BioNTech SE	27.32 Bn	8.93 Bn	668.28 Mn
8	Royalty Pharma	27.29 Bn	26.45 Bn	-
9	Insmed	26.99 Bn	25.83 Bn	358.27 Mn
10	OSR Health	1.40 Mn	20.39 Mn	86,605.00

Download Data